RxDoctor Payments DataLook up a doctor →

Ronald Ralph, MD

Internal Medicine · Houston, TXNPI 1467412916

Payments from drug & device makers

$2,688,232in general payments, 2019–2025

Across 643 payments — averaging $4180.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$1.2M
  • AstraZeneca$700K
  • CSL Behring$410K
  • Astrazeneca UK Limited$103K
  • Bayer$86K
  • Akebia Therapeutics Inc$63K
  • plus $135K from 38 others

What the payments were for

  • Food & beverage$7,50899%
  • Education$381%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,688,232 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$175,619
Medicare patients
207
Services billed
1,338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol255$170,269
RayaldeeCalcifediol58$125,680
IngrezzaValbenazine Tosylate13$108,143
OzempicSemaglutide87$101,905
KerendiaFinerenone74$66,746
JardianceEmpagliflozin84$63,473
MounjaroTirzepatide25$31,841
EliquisApixaban38$28,205
Sevelamer Carbonate34$7,697
RetacritEpoetin Alfa-Epbx18$6,931
LokelmaSodium Zirconium Cyclosilicate16$5,877
Nifedipine ErNifedipine104$4,347
Telmisartan104$3,977
Paricalcitol30$2,531
Midodrine Hcl21$2,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$699,843$176,146271 claims
OPKO Pharmaceuticals, LLCRayaldee$561$125,68058 claims
Novo NordiskOzempic$75$101,90587 claims
BayerKerendia$85,951$66,74674 claims
Boehringer IngelheimJardiance$173$63,47384 claims
Lilly USA, LLCMounjaro$192$31,84125 claims
ANI Pharmaceuticals, Inc.Valsartan$122$37013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →